Binge Eating Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Binge Eating Disorder Treatment Market is projected to expand from USD 708.15 million in 2025 to USD 1.07 billion by 2031, reflecting a CAGR of 7.21%. This market encompasses a range of pharmacotherapeutic agents and evidence-based psychotherapies aimed at reducing compulsive overeating episodes and treating associated psychological conditions.

Key growth drivers include the rising global prevalence of eating disorders and higher diagnosis rates resulting from enhanced mental health awareness. Additionally, regulatory approvals for central nervous system stimulants continue to widen therapeutic options. As noted by the Alliance for Eating Disorders in 2024, Binge Eating Disorder is the most prevalent eating disorder among U.S. adults, affecting three times as many individuals as Anorexia Nervosa and Bulimia Nervosa combined.

Despite these positive indicators, the market confronts major obstacles due to the high costs associated with specialized treatment and insufficient insurance coverage, which limits patient access. This financial strain is particularly severe in developing regions where mental health infrastructure lacks adequate funding, creating a significant disparity between the number of potential patients and those receiving effective care. Consequently, the scarcity of affordable therapeutic alternatives could seriously restrict revenue potential for manufacturers, especially within price-sensitive international markets.

Market Drivers

A primary engine for market growth is the robust clinical pipeline and drug development activity, marked by a transition toward novel mechanisms of action that go beyond traditional stimulants. Pharmaceutical firms are aggressively pushing late-stage trials to mitigate the shortage of FDA-approved therapies, drawing substantial investment into the sector. For instance, Axsome Therapeutics announced in a corporate press release in April 2024 the launch of the ENGAGE Phase 3 trial to assess solriamfetol, a dopamine and norepinephrine reuptake inhibitor, for treating adults with Binge Eating Disorder. This increase in clinical activity also encompasses alternative therapeutic classes, such as psychedelic-assisted treatments; Tryptamine Therapeutics reported in a November 2024 clinical update that it had completed subject dosing in a Phase 1b trial for TRP-8803, an IV-infused psilocin formulation.

Government initiatives and favorable reimbursement policies play an equally vital role in enhancing market accessibility and affirming the medical necessity of treatment. Legislators are increasingly designating funds to close the gap between diagnosis and effective care, particularly within underserved primary care environments where early detection is essential.

This commitment is reflected in federal budgets aimed at improving provider training and infrastructure. According to an April 2024 report by the Eating Disorders Coalition regarding the Fiscal Year 2024 Funding Package, the organization secured $1 million specifically to train primary healthcare providers in screening, brief intervention, and referral to treatment (SBIRT). These policy achievements not only reduce stigma but also encourage healthcare systems to adopt specialized BED therapies, expanding the commercial reach for providers worldwide.

Market Challenges

The high expense of specialized care combined with insufficient insurance reimbursement represents a major hurdle to the growth of the Global Binge Eating Disorder Treatment Market. This economic barrier limits patient access to essential pharmacotherapeutic agents and psychotherapies, effectively shrinking the addressable market size. When patients encounter prohibitive out-of-pocket costs and insurance plans lack comprehensive coverage for long-term management, high diagnostic rates fail to convert into treated cases. This gap severely restricts revenue generation for pharmaceutical manufacturers and healthcare providers, particularly in areas where public health funding cannot cover the financial shortfall.

The scale of this financial burden is significant. As reported by the Butterfly Foundation in 2024, the total economic and social cost of eating disorders in Australia was estimated at $66.9 billion, with per-person costs averaging approximately $60,654. Such high individual expenses underscore an affordability crisis that precludes a large portion of the diagnosed population from obtaining consistent care. As a result, these financial obstacles hinder the market's capacity to leverage rising diagnostic trends, thereby stalling growth in both developed nations and price-sensitive international regions.

Market Trends

The integration of digital therapeutics and mobile health applications is fundamentally transforming the market by removing geographical and logistical obstacles to effective care. Virtual-first care models are securing significant traction and investor confidence, supporting a shift toward remote, scalable interventions that augment traditional Binge Eating Disorder therapy. This digital evolution enables providers to access underserved populations and administer evidence-based treatments directly to patients' homes, circumventing the capacity limits of physical facilities. Highlighting this trend, Behavioral Health Business reported in August 2025 that virtual provider Equip Health raised nearly $47 million in new equity funding to meet the growing demand for accessible, technology-enabled remote care.

Simultaneously, the market is experiencing a strategic consolidation of specialized treatment centers as major behavioral health networks refine their portfolios to focus on clinical quality and operational efficiency. In this competitive environment, consolidated entities are emphasizing rigorous data collection to prove treatment efficacy, thereby securing payer reimbursement and distinguishing their care models from fragmented competitors. Large-scale providers are increasingly utilizing network-wide outcome data to validate their residential and outpatient protocols. For example, Odyssey Behavioral Healthcare’s October 2025 '2024 Treatment Outcomes Report' indicated that adults in their residential eating disorder programs achieved a 51% overall reduction in symptoms, demonstrating the clinical value delivered by these specialized, consolidated systems.

Key Players Profiled in the Binge Eating Disorder Treatment Market

• Viatris Inc.
• Johnson & Johnson Services, Inc.
• Lupin Ltd.
• Omeros Corp.
• Pyramid Healthcare Inc.
• Sumitomo Pharma Co. Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Eli Lilly and Co
• Tonix Pharmaceuticals Holding Corp.
• Tryp Therapeutics Inc.

Report Scope

In this report, the Global Binge eating Disorder Treatment Market has been segmented into the following categories:

Binge eating Disorder Treatment Market, by Type:

• Antidepressants
• Anticonvulsants
• Stimulants
• Others

Binge eating Disorder Treatment Market, by Distribution Channel:

• Offline
• Online

Binge eating Disorder Treatment Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Binge eating Disorder Treatment Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.